SynthesisTropical medicine & international health : TM & IH2025
Burden of Chikungunya Fever and Its Economic and Social Impacts Worldwide: A Systematic Review.
Synthesis in Tropical medicine & international health : TM & IH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Burden of Chikungunya Fever and Its Economic and Social Impacts Worldwide: A Systematic Review.Tropical medicine & international health : TM & IH · 2025Pooled it
- Acute-phase clinical profile and quality of life in patients with chikungunya during the 2025 outbreak in Bangladesh: A facility-based cross-sectional study.PLoS neglected tropical diseases · 2026Article
- Luciferase unleashed: Lighting the path to vaccine approval using a novel high-throughput chikungunya virus neutralization assay.PLoS neglected tropical diseases · 2026Article
- Circulating miR-146a-5p and miR-98-5p as Indicators of Inflammatory Response and Joint Pain in Chikungunya Fever.Virus research · 2026Article
- Climate change and budget cuts: Facing theMalariaWorld journal · 2026Article
- Chikungunya fever: a re-emerging mosquito-borne threat demanding proactive prevention strategies in Asia.Frontiers in public health · 2026Article
- Guiding vaccine policy for chikungunya in Brazil: a cost-effectiveness analysis of live-attenuated versus recombinant chikungunya vaccines in Brazilian adults ≥18 years.BMJ public health · 2026Article
- Chikungunya fever: pathogenesis and mechanisms underlying pain symptoms.Frontiers in immunology · 2025Review
- Quality and reliability evaluation of chikungunya fever-related video content on Tiktok and Bilibili: A cross-sectional study.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to investigate the social and economic impacts and disease burden of Chikungunya Fever globally through a systematic literature review.
methodsWe performed a comprehensive literature search through MEDLINE (via PubMed), LILACS, and Embase databases, and grey literature, including studies of populations diagnosed with Chikungunya Fever or at risk of infection published in English, Spanish, French, or Portuguese, without date restrictions. Two reviewers independently performed study selection, data extraction, and quality assessment. Methodological quality was assessed using different tools.
resultsForty-three publications were included. Until 2013, publications originated solely from the Asian and African continents. From 2015 onwards, South America emerged as the predominant source. Publications were classified as cost studies (25), including cost-of-illness (18) and program cost (6); burden of disease studies (10); cost-outcome studies (4), including cost-effectiveness (3) and cost-utility (1); and quality-of-life studies (15). Reported total direct costs associated with Chikungunya Fever ranged from US$ 3.5 million (US Virgin Islands, 2014-2015) to US$ 83.6 billion (Region of the Americas, 2013-2015). Direct medical costs varied from US$ 308.94 (Tamil Nadu, India, 2006) to US$ 33.7 million (Réunion Island, 2005-2006). Vector control program costs ranged from US$ 888,000 annually (Greece, 2013-2017) to US$ 466 million (Brazil, 2016). Estimated disability-adjusted life years per 100,000 population ranged from 4.53 (India, 2006) to 2432 (Region of the Americas, 2013-2015). Quality-of-life studies demonstrated substantial declines across multiple domains, indicating significant functional impairment due to Chikungunya Fever.
conclusionChikungunya Fever imposes a considerable economic and social burden, surpassing that of other endemic arboviral diseases such as dengue and yellow fever. These findings underscore the need for further research to accurately quantify the full scope of Chikungunya Fever-related costs and impacts on affected populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.